Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2011

Jul 16, 2011

32418_dirs_2011-07-15_320c41a2-3de9-4c7b-bfad-549037fe5aa3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC.OB)
CIK: 0001386570
Period of Report: 2011-07-13

Reporting Person: Brauser Michael (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-07-13 Warrant to Purchase Common Stock $0.21 P 100000 Acquired 2013-05-20 Common Stock (100000) Direct